19-10996498-C-T
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBP6
The NM_001387283.1(SMARCA4):c.1766C>T(p.Ala589Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,874 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A589T) has been classified as Likely benign.
Frequency
Consequence
NM_001387283.1 missense
Scores
Clinical Significance
Conservation
Publications
- Coffin-Siris syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
- intellectual disability, autosomal dominant 16Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- rhabdoid tumor predisposition syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- uterine corpus sarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- familial rhabdoid tumorInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA4 | ENST00000646693.2 | c.1766C>T | p.Ala589Val | missense_variant | Exon 11 of 36 | NM_001387283.1 | ENSP00000495368.1 | |||
SMARCA4 | ENST00000344626.10 | c.1766C>T | p.Ala589Val | missense_variant | Exon 11 of 35 | 1 | NM_003072.5 | ENSP00000343896.4 | ||
SMARCA4 | ENST00000643549.1 | c.1766C>T | p.Ala589Val | missense_variant | Exon 11 of 35 | ENSP00000493975.1 | ||||
SMARCA4 | ENST00000541122.6 | c.1766C>T | p.Ala589Val | missense_variant | Exon 12 of 35 | 5 | ENSP00000445036.2 | |||
SMARCA4 | ENST00000643296.1 | c.1766C>T | p.Ala589Val | missense_variant | Exon 11 of 34 | ENSP00000496635.1 | ||||
SMARCA4 | ENST00000644737.1 | c.1766C>T | p.Ala589Val | missense_variant | Exon 11 of 34 | ENSP00000495548.1 | ||||
SMARCA4 | ENST00000589677.5 | c.1766C>T | p.Ala589Val | missense_variant | Exon 12 of 35 | 5 | ENSP00000464778.1 | |||
SMARCA4 | ENST00000643995.1 | c.1178C>T | p.Ala393Val | missense_variant | Exon 8 of 32 | ENSP00000496004.1 | ||||
SMARCA4 | ENST00000644963.1 | c.410C>T | p.Ala137Val | missense_variant | Exon 4 of 28 | ENSP00000495599.1 | ||||
SMARCA4 | ENST00000643857.1 | c.119C>T | p.Ala40Val | missense_variant | Exon 2 of 25 | ENSP00000494159.1 | ||||
SMARCA4 | ENST00000644065.1 | c.491C>T | p.Ala164Val | missense_variant, splice_region_variant | Exon 4 of 27 | ENSP00000493615.1 | ||||
SMARCA4 | ENST00000642350.1 | c.251C>T | p.Ala84Val | missense_variant, splice_region_variant | Exon 3 of 27 | ENSP00000495355.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461874Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 727240 show subpopulations
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SMARCA4 protein function. ClinVar contains an entry for this variant (Variation ID: 470258). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 589 of the SMARCA4 protein (p.Ala589Val). -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.A589V variant (also known as c.1766C>T), located in coding exon 10 of the SMARCA4 gene, results from a C to T substitution at nucleotide position 1766. The alanine at codon 589 is replaced by valine, an amino acid with similar properties. Missense and in-frame variants in SMARCA4 are known to cause neurodevelopmental disorders; however, such associations with rhabdoid tumor predisposition syndrome including small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) are exceedingly rare (Kosho T et al. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):262-75; Jelinic P et al. Nat Genet. 2014 May;46(5):424-6). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the supporting evidence, the association of this alteration with Coffin-Siris syndrome is unknown; however, the association of this alteration with rhabdoid tumor predisposition syndrome is unlikely. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at